(2R,4R)-2-hydroxymethyl-4-trifluoromethyl-N-[(1,1-dimethyl)ethoxycarbonyl]pyrrolidine | 497103-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2R,4R)-2-hydroxymethyl-4-trifluoromethyl-N-[(1,1-dimethyl)ethoxycarbonyl]pyrrolidine
• 英文别名: (2R,4R)-tert-butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate；tert-Butyl (2R,4R)-2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate
• CAS: 497103-76-1
• 化学式: C₁₁H₁₈F₃NO₃
• 分子量: 269.264
• InChiKey: CRSWFECHMDRHHV-HTQZYQBOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2R,4R)-2-hydroxymethyl-4-trifluoromethyl-N-[(1,1-dimethyl)ethoxycarbonyl]pyrrolidine 在 盐酸 、 copper(l) iodide 、 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 三乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 二甲基亚砜 、 乙酸乙酯 、 正丁醇 为溶剂， 90.0 ℃ 、101.33 kPa 条件下， 反应 10.0h， 生成 methyl 2-((2R,4R)-1-(4-hydroxyphenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetate
  参考文献：
  名称：

  Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

  摘要：

  G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote,glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly I selectiveand potent GPR40 agonists with a dual mechanism of action, promoting both ghicose-clependent insulin and incretin secretion. Employing strategies to increase fiolarity and the ratio of sp(3)/sP(2) character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

  DOI：

  10.1021/acs.jmedchem.7b00982
• 作为产物：
  描述：

  顺式-4-羟基-D-脯氨酸盐酸盐 在 N-甲基吗啉 、 吡啶 、 chromium(VI) oxide 、 sodium tetrahydroborate 、 氯化亚砜 、 硫酸 、 palladium 10% on activated carbon 、 四丁基氟化铵 、 氢气 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 丙酮 为溶剂， -10.0~110.0 ℃ 、101.33 kPa 条件下， 反应 16.92h， 生成 (2R,4R)-2-hydroxymethyl-4-trifluoromethyl-N-[(1,1-dimethyl)ethoxycarbonyl]pyrrolidine
  参考文献：
  名称：

  Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

  摘要：

  G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote,glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly I selectiveand potent GPR40 agonists with a dual mechanism of action, promoting both ghicose-clependent insulin and incretin secretion. Employing strategies to increase fiolarity and the ratio of sp(3)/sP(2) character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

  DOI：

  10.1021/acs.jmedchem.7b00982

文献信息

• [EN] PYRROLIDINE GPR40 MODULATORS<br/>[FR] MODULATEURS PYRROLIDINES DE GPR40
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014078609A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物：或其立体异构体，或其药物可接受的盐，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。
• [EN] PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES À MÉDIATION PAR COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2022066774A1

  公开（公告）日：2022-03-31

  This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement C1-mediated disorders.

  这份披露提供了用于治疗医学障碍的药物化合物，例如补体介导的障碍，包括补体C1介导的障碍。
• Synthesis of Boc-protected cis- and trans-4-trifluoromethyl-d-prolines
  作者：Xiao-long Qiu、Feng-ling Qing

  DOI：10.1039/b206719f

  日期：2002.9.11

  Both Boc-protected trans- and cis-4-trifluoromethyl prolines were synthesized starting from L-serine simultaneously. In our synthetic route, the key intermediate 4 was obtained through the reaction of Garner's aldehyde 1 with ylide 2 followed by trifluoromethylation with FSO2CF2COOMe–CuI. After hydrogenation followed by reduction of 4, the alcohol 5 was obtained in low diastereoselectivity, however, the two diastereoisomers could be separated easily by flash chromatography in the following steps. The bromide 8b obtained from the alcohol 5 in a straightforward fashion could not afford the desired cyclization product because of the strong electron-withdrawing properties of the trifluoromethyl group and the low ability of bromide as a leaving group. Instead, mesylation of alcohols 12a and 12b followed by treatment with potassium bis(trimethylsilyl)amide (KHMDS) afforded the desired cyclization products 13a and 13b respectively, which were transformed into Boc-protected cis- and trans-4-trifluoromethyl-D-prolines in a straightforward fashion.

  同时从L-丝氨酸出发，合成了Boc保护的反式和顺式4-三氟甲基脯氨酸。在我们的合成路线中，关键中间体4是通过加纳醛1与亚胺2反应，然后用FSO2CF2COOMe-CuI进行三氟甲基化反应获得的。在4氢化和还原后，获得了低立体选择性醇5，然而，通过以下步骤的快速色谱法可以很容易地将两种非对映异构体分离。由于三氟甲基基团的强吸电子性和溴化物作为离开基团的低能力，从醇5中直接获得的溴化物8b不能提供所需的环化产物。相反，醇12a和12b的甲磺化，然后用双(三甲基硅基)氨基钾(KHMDS)处理，分别得到了所需的环化产物13a和13b，它们被直接转化为Boc保护的顺式和反式4-三氟甲基-D-脯氨酸。
• Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
  作者：Jun Shi、Zhengxiang Gu、Elizabeth Anne Jurica、Ximao Wu、Lauren E. Haque、Kristin N. Williams、Andres S. Hernandez、Zhenqiu Hong、Qi Gao、Marta Dabros、Akin H. Davulcu、Arvind Mathur、Richard A. Rampulla、Arun Kumar Gupta、Ramya Jayaram、Atsu Apedo、Douglas B. Moore、Heng Liu、Lori K. Kunselman、Edward J. Brady、Jason J. Wilkes、Bradley A. Zinker、Hong Cai、Yue-Zhong Shu、Qin Sun、Elizabeth A. Dierks、Kimberly A. Foster、Carrie Xu、Tao Wang、Reshma Panemangalore、Mary Ellen Cvijic、Chunshan Xie、Gary G. Cao、Min Zhou、John Krupinski、Jean M. Whaley、Jeffrey A. Robl、William R. Ewing、Bruce Alan Ellsworth

  DOI：10.1021/acs.jmedchem.7b00982

  日期：2018.2.8

  G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote,glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly I selectiveand potent GPR40 agonists with a dual mechanism of action, promoting both ghicose-clependent insulin and incretin secretion. Employing strategies to increase fiolarity and the ratio of sp(3)/sP(2) character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.